https://cefaclorchemical.com/h....ibernation-factors-r
Link between 598 studies screened, 101 had been eligible 16 had been potential (15.8%). The qualified studies included a total of 5,545 NEN customers, with a median of 39 patients per study (range 5-214). Pooled price of partial response was 36.6% (38.9% accomplished stable disease) and 55.2% of patients had a symptomatic reaction to therapy when pooled information were analysed. The median PFS and OS were 18.4 months (95% CI 15.5-21.2) and 40.7 months (95% CI 35.2-46.2), resp
Like
Comment
Share
